Karboplatin Accord (Carboplatin)

Carboplatin forms reactive platinum complexes inside cancer cells that bind to DNA, creating cross‑links that block DNA replication and transcription. This DNA damage triggers programmed cell death, preferentially affecting rapidly dividing tumour cells while sparing most normal tissues.

The dose of carboplatin is individualized based on the patient’s body surface area, renal function and the specific chemotherapy protocol. The prescribing oncologist determines the exact amount and schedule for each treatment cycle.

Carboplatin is classified as contraindicated in pregnancy unless the potential benefit justifies the risk to the fetus. It is also not recommended for breastfeeding mothers because the drug can be excreted in milk. Consultation with a specialist is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Both carboplatin and cisplatin are platinum‑based agents, but carboplatin generally has a more favorable toxicity profile, causing less severe nausea, vomiting and nephrotoxicity. However, carboplatin may produce more myelosuppression. Choice of agent depends on tumour type, patient tolerance and physician preference.

Karboplatin Accord should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen. The vial should be kept in its original packaging until use and handled with aseptic technique to maintain sterility.

The drug is given as an intravenous infusion, typically over 30‑60 minutes, depending on the prescribed dose and protocol. Administration is performed by qualified healthcare professionals in a clinical setting, with appropriate monitoring for infusion reactions.

The most serious risks include severe myelosuppression leading to infection or bleeding, allergic or anaphylactic reactions, renal impairment, ototoxicity and, rarely, secondary leukemias. Patients should be closely monitored for blood counts, kidney function and any signs of hypersensitivity.

Patients with known hypersensitivity to carboplatin or other platinum compounds, those with severe renal impairment (creatinine clearance < 30 mL/min), uncontrolled infections, or pregnant women (unless benefits outweigh risks) should not receive this medication.